Skip to main content

Table 4 Multivariable linear regression analyses for factors associated with changes in lipid levels from switch to ≥48 weeks on second-line ART

From: Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study

At switch to second- line*

n (%) or median (IQR)

TC effect (se)

P

LDL-C effect (se)

P

HDL-Ceffect (se)

P

TG effect (se)

P

Gender

         

  Females

32 (48%)

+04 (0.3)

0.14

+0.5 (0.2)

0.04

+0.1 (0.08)

0.26

−0.07 (0.3)

0.81

Age (per 10 year increase)

38 (34-43)

+0.4 (0.2)

0.02

+0.3 (0.1)

0.06

+0.1 (0.06)

0.02

−0.04 (0.2)

0.87

BMI (kg/m2) per 2 units

21 (17-26)

+0.02 (0.03)

0.47

+0.02 (0.03)

0.41

−0.02 (0.01)

0.08

+0.08 (0.04)§

0.07

NVP

50 (77%)

+1.3 (0.4)

0.004

+0.6 (0.3)

0.10

+0.6 (0.2)

<0.001

+0.4 (0.6)

0.43

EFV

9 (14%)

+1.6 (0.5)

0.003

+0.9 (0.4)

0.03

+0.4 (0.2)

0.02

+0.4 (0.6)

0.57

ddI

34 (52%)

−0.04 (0.3)

0.88

−0.1 (02)

0.54

−0.1 (0.1)

0.21

+0.2 (0.3)

0.54

  1. Al l models are adjusted for baseline lipid level.
  2. §BMI at week 48 (rather than at switch to second-line) as this was a better predictor.
  3. *Reference category: man aged 40 years with BMI 25 at switch, receiving LPV/r plus NRTIs (no NNRTI) without ddI as their second-line regimen.